MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.75
-0.68
-2.03%
After Hours: 32.75 0 0.00% 16:17 07/10 EDT
OPEN
33.19
PREV CLOSE
33.43
HIGH
33.58
LOW
31.36
VOLUME
101.38K
TURNOVER
--
52 WEEK HIGH
42.26
52 WEEK LOW
19.10
MARKET CAP
659.87M
P/E (TTM)
-50.9410
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KROS stock price target is 43.50 with a high estimate of 50.00 and a low estimate of 37.00.

EPS

KROS News

More
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Keros Therapeutics To Join Russell 2000 Index
LEXINGTON, Mass, June 26, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery,
Benzinga · 06/26 11:03
Keros Therapeutics Set to Join Russell 2000® Index
Keros Therapeutics, Inc. (“Keros” or the “Company”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with
GlobeNewswire · 06/26 11:01
Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher
Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 06/24 12:34
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15
Keros Therapeutics Highlihts Presentation Of Results From Clinical And Preclinical Studies Investigating KER-050, Along With Preclinical Data From Its ALK2 Inhibitor Program, At European Hematology Association 2020 Annual Meeting
  Poster presentation highlights Phase 1 clinical trial data demonstrating tolerability, pharmacokinetics and pharmacodynamics of KER-050 in healthy postmenopausal women. Poster presentations introduce data
Benzinga · 06/12 11:02
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting
Poster presentations introduce data demonstrating KER-050 robustly promoted hematopoiesis in multiple animal species in preclinical studies and support a potentially novel mechanism of action. Oral presentation on a novel ALK2 kinase inhibitor that suppressed
GlobeNewswire · 06/12 11:01
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 12:13

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About KROS

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressive. KER-047 is in a Phase I clinical trial. Its KER-012 is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
More

Webull offers kinds of Keros Therapeutics Inc stock information, including NASDAQ:KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.